Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy.

Colorectal cancer (CRC) is presently the third deadliest cancer in the world. This malignant cancer usually precedes the progression of precancerous lesions, and it is challenging to distinguish its nuanced morphological changes. Molecular-based near-infrared-II (NIR-II) fluorescence imaging can effectively recognize lesion targets to improve image contrast and increase early tumor detection compared with traditional wide-light screening endoscopy. c-Met has been determined to be overexpressed in advanced stages of CRC and is considered to be a potent tumor biomarker. Herein, based on the well-targeted inhibitory effect of Crizotinib on c-Met positive tumor cells, the dye IR808 was covalently combined with the drug molecule Crizotinib, resulting in the synthesis of a NIR fluorescent probe Crizotinib-IR808 targeting c-Met positive tumor cells. Then, water-insoluble Crizotinib-IR808 was fabricated by using bovine serum albumin (BSA) nanoparticles (NPs) with excellent biocompatibility and biosafety. The prepared Crizotinib-IR808@BSA NPs showed tumor targeting capability as well as use for noninvasive biomedical vascular NIR-II imaging with intraoperative real-time NIR-II imaging to guide tumor resection. Under 808 nm laser irradiation, Crizotinib-IR808@BSA NPs exhibited synergistic chemophototherapy effects on tumors. In conclusion, this innovative imaging-mediated multifunctional combination therapy strategy with good c-Met targeting ability may provide a new approach for colorectal cancer treatment.